Breast density and breast cancer risk: A practical review

Mayo Clinic Proceedings

Volumn 89, Issue 4, 2014, Pages 548-557

  Wang, Amy T ^a   Vachon, Celine M ^b   Brandt, Kathleen R ^c   Ghosh, Karthik ^a  

^a MAYO CLINIC   (United States)

^b Department of Health Sciences Research ^*  (United States)

^c Mayo Clinic College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TAMOXIFEN;

AGING; BREAST; BREAST CANCER; BREAST DENSITY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DIGITAL MAMMOGRAPHY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; HIGH RISK PATIENT; HUMAN; PATIENT COUNSELING; REVIEW; RISK ASSESSMENT; WOMEN'S HEALTH;

ADULT; AGED; BIOPSY, NEEDLE; BREAST; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMOGRAPHY; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PRECANCEROUS CONDITIONS; RISK ASSESSMENT; TIME FACTORS; ULTRASONOGRAPHY, MAMMARY;

EID: 84898623870     PISSN: 00256196     EISSN: 19425546     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.12.014     Document Type: Review

References (72)

1. Grady D. Laws add dimension, and questions, to breast cancer screening. New York Times. October 25, 2012:A1.
2. Breast Density and Mammography Reporting Act of 2011; 2011. American College of Radiology. The American College of Radiology Breast Imaging Reporting and Data System (BI-RADS). 4th ed. Reston, VA: American College of Radiology; 2003
3. BCSC Data Explorer. NCI-funded Breast Cancer Surveillance Consortium (HHSN261201100031C). Downloaded on 11 November 2013 from the Breast Cancer Surveillance Consortium website, http://breastscreening.cancer.gov/. Accessed November 11, 2013.
4. Sickles EA. The use of breast imaging to screen women at high risk for cancer. Radiol Clin North Am. 2010;48(5):859-878.
5. Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ. The quantitative analysis of mammographic densities. Phys Med Biol. 1994; 39(10):1629-1638.
6. Kerlikowske K, Grady D, Barclay J, et al. Variability and accuracy in mammographic interpretation using the American College of Radiology Breast Imaging Reporting and Data System. J Natl Cancer Inst. 1998;90(23):1801-1809.
7. Ciatto S, Houssami N, Apruzzese A, et al. Categorizing breast mammographic density: intra-and interobserver reproducibility of BI-RADS density categories. Breast. 2005;14(4):269-275.
8. Heine JJ, Scott CG, Sellers TA, et al. A novel automated mammographic density measure and breast cancer risk [published correction appears in J Natl Cancer Inst. 2012;104(21): 1687-1690]. J Natl Cancer Inst. 2012;104(13):1028- 1037.
9. Li J, Szekely L, Eriksson L, et al. High-throughput mammographicdensity measurement: a tool for risk prediction of breast cancer. Breast Cancer Res. 2012;14(4):R114.
10. Shepherd JA, Kerlikowske K, Ma L, et al. Volume of mammographic density and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(7):1473-1482.
11. Skippage P, Wilkinson L, Allen S, Roche N, Dowsett M, A'Hern R. Correlation of age and HRT use with breast density as assessed by Quantra. Breast J. 2013;19(1):79-86.
12. Ciatto S, Bernardi D, Calabrese M, et al. A first evaluation of breast radiological density assessment by QUANTRA software as compared to visual classification. Breast. 2012;21(4):503-506.
13. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007; 356(3):227-236.
14. Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography [published correction appears in Ann Intern Med. 2003;138(9): 771]. Ann Intern Med. 2003;138(3):168-175.
15. Harvey JA, Bovbjerg VE. Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology. 2004;230(1):29-41.
16. Mandelson MT, Oestreicher N, Porter PL, et al. Breast density as a predictor of mammographic detection: comparison of interval-and screen-detected cancers. J Natl Cancer Inst. 2000; 92(13):1081-1087.
17. Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology. 2002;225(1): 165-175.
18. Vachon CM, van Gils CH, Sellers TA, et al. Mammographic density, breast cancer risk and risk prediction. Breast Cancer Res. 2007;9(6):217.
19. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(6):1159-1169.
20. Byrne C, Schairer C, Wolfe J, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst. 1995;87(21):1622-1629.
21. Kerlikowske K, Cook AJ, Buist DS, et al. Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use. J Clin Oncol. 2010;28(24):3830-3837.
22. Maskarinec G, Pagano I, Chen Z, Nagata C, Gram IT. Ethnic and geographic differences in mammographic density and their association with breast cancer incidence. Breast Cancer Res Treat. 2007;104(1):47-56.
23. Ursin G, Ma H, Wu AH, et al. Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev. 2003;12(4):332-338.
24. Santen RJ, Boyd NF, Chlebowski RT, et al; Breast Cancer Prevention Collaborative Group. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer. 2007;14(2):169-187.
25. Price ER, Hargreaves J, Lipson JA, et al. The California Breast Density Information Group: a collaborative response to the issues of breast density, breast cancer risk, and breast density notification legislation. Radiology. 2013;269(3):887-892.
26. Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst. 1995;87(9):670-675.
27. Vacek PM, Geller BM. A prospective study of breast cancer risk using routine mammographic breast density measurements. Cancer Epidemiol Biomarkers Prev. 2004;13(5):715-722.
28. Bertrand KA, Tamimi RM, Scott CG, et al. Mammographic density and risk of breast cancer by age and tumor characteristics. Breast Cancer Res. 2013;15(6):R104.
29. Eriksson L, Czene K, Rosenberg L, Humphreys K, Hall P. Possible influence of mammographic density on local and locoregional recurrence of breast cancer. Breast Cancer Res. 2013;15(4):R56.
30. Park CC, Rembert J, Chew K, Moore D, Kerlikowske K. High mammographic breast density is independent predictor of local but not distant recurrence after lumpectomy and radiotherapy for invasive breast cancer. Int J Radiat Oncol Biol Phys. 2009; 73(1):75-79.
31. Gierach GL, Ichikawa L, Kerlikowske K, et al. Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium. J Natl Cancer Inst. 2012;104(16):1218-1227.
32. Zhang S, Ivy JS, Diehl KM, Yankaskas BC. The association of breast density with breast cancer mortality in African American and white women screened in community practice. Breast Cancer Res Treat. 2013;137(1):273-283.
33. Checka CM, Chun JE, Schnabel FR, Lee J, TothH. The relationship of mammographic density and age: implications for breast cancer screening. AJR Am J Roentgenol. 2012;198(3):W292-W295.
34. Lokate M, Stellato RK, Veldhuis WB, Peeters PH, van Gils CH. Age-related changes in mammographic density and breast cancer risk. Am J Epidemiol. 2013;178(1):101-109.
35. McTiernan A, Martin CF, Peck JD, et al; Women's Health Initiative Mammogram Density Study Investigators. Estrogen-plusprogestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst. 2005;97(18):1366-1376.
36. Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA. Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control. 2000;11(7):653-662.
37. Boyd NF, Lockwood GA, Byng JW, Little LE, Yaffe MJ, Tritchler DL. The relationship of anthropometric measures to radiological features of the breast in premenopausal women. Br J Cancer. 1998;78(9):1233-1238.
38. Boyd NF, Martin LJ, Sun L, et al. Body size, mammographic density, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2086-2092.
39. Cuzick J,Warwick J, Pinney E, et al. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst. 2011;103(9):744-752.
40. Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst. 2004;96(8):621-628.
41. Kim J, Han W, Moon HG, et al. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer. Breast Cancer Res. 2012;14(4):R102.
42. Li J, Humphreys K, Eriksson L, Edgren G, Czene K, Hall P. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer. J Clin Oncol. 2013; 31(18):2249-2256.
43. Cigler T, Tu D, Yaffe MJ, et al. A randomized, placebocontrolled trial (NCIC CTG MAP1) examining the effects of letrozole on mammographic breast density and other end organs in postmenopausal women. Breast Cancer Res Treat. 2010;120(2):427-435.
44. Vachon CM, Ingle JN, Suman VJ, et al. Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen. Breast. 2007;16(2):204-210.
45. Vachon CM, Suman VJ, Brandt KR, et al. Mammographic breast density response to aromatase inhibition. Clin Cancer Res. 2013; 19(8):2144-2153.
46. Kelemen LE, Pankratz VS, Sellers TA, et al. Age-specific trends in mammographic density: the Minnesota Breast Cancer Family Study. Am J Epidemiol. 2008;167(9):1027-1036.
47. Prowell TM, Blackford AL, Byrne C, et al. Changes in breast density and circulating estrogens in postmenopausal women receiving adjuvant anastrozole. Cancer Prev Res (Phila). 2011; 4(12):1993-2001.
48. Smith J, Dilawari A, Ursin G, et al. A pilot study of letrozole for one year in women at enhanced risk of developing breast cancer: effects on mammographic density. Anticancer Res. 2012; 32(4):1327-1331.
49. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509-518.
50. Saslow D, Boetes C, Burke W, et al; American Cancer Society Breast Cancer Advisory Group. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57(2):75-89.
51. Tice JA, Cummings SR, Smith-Bindman R, Ichikawa L, Barlow WE, Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med. 2008;148(5):337-347.
52. Barlow WE, White E, Ballard-Barbash R, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst. 2006;98(17):1204-1214.
53. Smith-Warner SA, Spiegelman D, Yaun SS, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA. 1998;279(7):535-540.
54. Chlebowski RT, Anderson GL, Gass M, et al; WHI Investigators. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304(15): 1684-1692.
55. Centers for Disease Control and Prevention. Fact Sheetsd Alcohol Use and Health. Atlanta, GA: Centers for Disease Control and Prevention; October 1, 2012.
56. Pisano ED, Gatsonis C, Hendrick E, et al. Digital Mammographic Imaging Screening Trial (DMIST) Investigators Group. Diagnostic performance of digital versus film mammography for breast-cancer screening [published correction appears in N Engl J Med. 2006;355(17):1840]. N Engl J Med. 2005;353(17): 1773-1783.
57. Ciatto S, Houssami N, Bernardi D, et al. Integration of 3D digital mammography with tomosynthesis for population breastcancer screening (STORM): a prospective comparison study. Lancet Oncol. 2013;14(7):583-589.
58. Haas BM, Kalra V, Geisel J, Raghu M, Durand M, Philpotts LE. Comparison of tomosynthesis plus digital mammography and digital mammography alone for breast cancer screening. Radiology. 2013;269(3):694-700.
59. Gur D, Zuley ML, Anello MI, et al. Dose reduction in digital breast tomosynthesis (DBT) screening using synthetically reconstructed projection images: an observer performance study. Acad Radiol. 2012;19(2):166-171.
60. Selenia Dimensions 3D System-P080003/S001. US Food and Drug Administration website. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/ cftopic/pma/pma.cfm?num=p080003s001. Accessed October 30, 2013.
61. Technology assessment No. 9: digital breast tomosynthesis. Obstet Gynecol. 2013;121(6):1415-1417.
62. Berg WA, Blume JD, Cormack JB, et al; ACRIN 6666 Investigators. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer [published correction appears in JAMA. 2010;303(15): 1482]. JAMA. 2008;299(18):2151-2163.
63. Berg WA, Zhang Z, Lehrer D, et al; ACRIN 6666 Investigators. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012; 307(13):1394-1404.
64. Weigert J, Steenbergen S. The Connecticut experiment: the role of ultrasound in the screening of women with dense breasts. Breast J. 2012;18(6):517-522.
65. Hooley RJ, Greenberg KL, Stackhouse RM, Geisel JL, Butler RS, Philpotts LE. Screening US in patients with mammographically dense breasts: initial experience with Connecticut Public Act 09-41. Radiology. 2012;265(1):59-69.
66. Sickles EA, Wolverton DE, Dee KE. Performance parameters for screening and diagnostic mammography: specialist and general radiologists. Radiology. 2002;224(3):861-869.
67. Kelly KM, Dean J, Comulada WS, Lee SJ. Breast cancer detection using automated whole breast ultrasound and mammography in radiographically dense breasts. Eur Radiol. 2010;20(3):734-742.
68. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292(11):1317-1325.
69. American College of Radiology. ACR Manual on Contrast Media. 9th ed. Reston, VA: American College of Radiology; 2013:97-98.
70. Rhodes DJ, Hruska CB, Phillips SW, Whaley DH, O'Connor MK. Dedicated dual-head gamma imaging for breast cancer screening in women with mammographically dense breasts. Radiology. 2011;258(1):106-118.
71. Rhodes DJ, Hruska CB, Conners AL, Maxwell RW, Tortorelli CL, O'Connor MK. Low-dose molecular breast imaging with Tc-99m sestamibi for screening in women with mammographically dense breasts: interim analysis. Paper presented at: Radiological Society of North America 2012 Scientific Assembly and Annual Meeting; November 2012; Chicago, IL.
72. Michailidou K, Hall P, Gonzalez-Neira A, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013;45(4):353-361:361e1-e2.